Application of nanoparticles to reverse multi-drug resistance in cancer

被引：7
|
作者：
Yang, Jie [1 ]
Zhang, Haijun [1 ]
Chen, Baoan [1 ]
机构：
[1] Southeast Univ, Sch Med, Zhongda Hosp, Dept Hematol & Oncol, Nanjing 210009, Jiangsu, Peoples R China
来源：
NANOTECHNOLOGY REVIEWS | 2016年 / 5卷 / 05期
关键词：
cancer; multi-drug resistance (MDR); nanoparticles (NPs); MESOPOROUS SILICA NANOPARTICLES; OVERCOME DRUG-RESISTANCE; VINCRISTINE SULFATE DELIVERY; SOLID LIPID NANOPARTICLES; BREAST-CANCER; CO-DELIVERY; MULTIFUNCTIONAL NANOPARTICLES; IN-VITRO; MAGNETIC NANOPARTICLES; HYALURONIC-ACID;
D O I：
10.1515/ntrev-2016-0023
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
Multi-drug resistance (MDR) poses a large obstacle to various human malignancies. For a long period, combination of multiple therapeutic agents has been the conventional method used to reverse MDR in cancer. However, it is still not an effective method as rather than cancer its serious side effects causes patient's death. Nanoparticles (NPs) are emerging as a class of therapeutics for cancer, including overcoming MDR. In the present review, we focus on the application of NPs to reverse MDR in cancer. Several kinds of NPs developed for the reversal of MDR are summarized. In addition, investigations in vitro and in vivo are also shown to highlight the advancement in the application of NPs to reverse MDR.
引用
收藏
页码：489 / 496
页数：8
相关论文
共 50 条
  • [1] Strategies to Overcome Multi-Drug Resistance in Cancer Cells: the Contribution of siRNA and Nanotechnologies
    Mambet, Cristina
    Chivu-Economescu, Mihaela
    Matei, Lilia
    Stoian, Mihai
    Bleotu, Coralia
    CURRENT ORGANIC CHEMISTRY, 2016, 20 (28) : 2971 - 2982
  • [2] LncRNA as a multifunctional regulator in cancer multi-drug resistance
    He, Jiaying
    Zhu, Shaomi
    Liang, Xin
    Zhang, Qinxiu
    Luo, Xiaohong
    Liu, Chi
    Song, Linjiang
    MOLECULAR BIOLOGY REPORTS, 2021, 48 (08) : 6151 - 6165
  • [3] The potential of multi-compound nanoparticles to bypass drug resistance in cancer
    Da Silva, C. G.
    Peters, Godefridus J.
    Ossendorp, Ferry
    Cruz, Luis J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (05) : 881 - 894
  • [4] Abnormal saccharides affecting cancer multi-drug resistance (MDR) and the reversal strategies
    Wang, Meizhu
    Chen, Wenming
    Chen, Jiansheng
    Yuan, Sisi
    Hu, Jiliang
    Han, Bangxing
    Huang, Yahui
    Zhou, Wen
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 220
  • [5] Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance
    Tekchandani, Pawan
    Das Kurmi, Balak
    Paliwal, Shivani Rai
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2017, 17 (18) : 1793 - 1810
  • [6] Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches
    Wu, Qiong
    Yang, Zhiping
    Nie, Yongzhan
    Shi, Yongquan
    Fan, Daiming
    CANCER LETTERS, 2014, 347 (02) : 159 - 166
  • [7] LncRNA as a multifunctional regulator in cancer multi-drug resistance
    Jiaying He
    Shaomi Zhu
    Xin Liang
    Qinxiu Zhang
    Xiaohong Luo
    Chi Liu
    Linjiang Song
    Molecular Biology Reports, 2021, 48 : 1 - 15
  • [8] Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells
    Miao, Jing
    Du, Yong-Zhong
    Yuan, Hong
    Zhang, Xing-guo
    Hu, Fu-Qiang
    COLLOIDS AND SURFACES B-BIOINTERFACES, 2013, 110 : 74 - 80
  • [9] Implications of nanotherapeutic advancements to leverage multi-drug resistant breast cancer: The state-of-the-art review
    Aravindan, Adhithya
    Gupta, Ashutosh
    Moorkoth, Sudheer
    Dhas, Namdev
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2024, 100
  • [10] Relationship between Methylation Status of Multi-drug Resistance Protein(MRP) and Multi-drug Resistance in Lung Cancer Cell Lines
    柳瑞军
    钟竑
    ChineseJournalofCancerResearch, 2007, (04) : 277 - 282
12345